Guanxin V for coronary artery disease: A retrospective study - 18/06/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Note: GXV: Guanxin V, GMT: guideline-recommended medical therapy.
Highlights |
• | Guanxin V is potentially safe and effective for coronary artery disease patients. |
• | Guanxin V significantly decreases the TSS and increased the 6-minute walk test. |
• | Guanxin V improves ejection fraction and cardiac output. |
• | Guanxin V reverses ventricular remodeling. |
Abstract |
Background |
Guanxin V (GXV), a traditional herbal mixture, has been widely used in clinical practice for the treatment of coronary artery disease (CAD). This retrospective study was designed to assess the safety and effectiveness of GXV for CAD.
Methods |
In our study, December 2006 to January 2009, 101 patients with CAD from Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine were enrolled, of whom 52 patients received GXV plus guideline-recommended medical therapy (GMT) (GXV group), 49 patients received GMT alone (GMT group). The general clinical information, traditional Chinese medicine syndrome score (TSS), the therapeutic effects, 6-minute walk test (6MWT), adverse events, echocardiography, and laboratory information were collected and analyzed pre-and post-treatment.
Results |
We did not find differences in the information between the two groups before treatment. Patients in the GXV group had decreased TSS (P < 0.0001) and increased therapeutic effects (P = 0.763) and 6MWT (P < 0.0001) than those in the GMT group and there were no significant differences in safety between the two groups. Moreover, patients in the GXV group improved ejection fraction, cardiac output, and stroke volume (P = 0.2113, 0.0001, 0.0002, respectively), and dropped BNP (P = 0.3856) compared with those in the GMT group.
Conclusions |
Superiority in the GXV group for patients with CAD was demonstrated over the GMT group for both the safety and effectiveness endpoints. This suggests that GXV is a potentially safe and effective treatment for CAD patients.
Le texte complet de cet article est disponible en PDF.Abbreviations : 6MWT, ACF, BNP, CAD, CO, EF, GMT, GXV, IQR, NYHA, QYB, SD, TCM, TSS
Keywords : Guanxin V, Coronary artery disease, Traditional Chinese medicine, Retrospective study
Plan
Vol 128
Article 110280- août 2020 Retour au numéro
Article précédent
- Parabens inhibit hNaV 1.2 channels
- Andrea Enrique, Pedro Martín, María Laura Sbaraglini, Alan Talevi, Verónica Milesi
- Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment
- Bo Chen, Yan Pan, Xin Xu, Fan Wu, Xuan Zheng, Si-Ye Chen, Yu-Ting Zhao, Zhou Huang, Shu-Hui Cheng, Jian-Xiang Liu, Wei-Hu Wang, Ye-Xiong Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?